Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6284061 | 0.85 | BCHE (0.47) | POLBTDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL14353586 | 0.74 | POLB (0.60) | POLBTDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL14353660 | 0.72 | POLB (0.51) | POLBTDP1MEN1KMT2A | |
| SCHEMBL6285702 | 0.72 | L3MBTL1 (0.46) | POLBTDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6284734 | 0.72 | POLB (0.42) | POLBTDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6281898 | 0.71 | KDM4E (0.41) | POLBTDP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL6282586 | 0.71 | BCHE (0.47) | POLBTDP1KMT2A | |
| SCHEMBL6285224 | 0.69 | ALDH1A1 (0.47) | MEN1KMT2A | |
| Ethylene SCHEMBL4597009 | 0.69 | NR4A1 (0.60) | L3MBTL1KDM4E | |
| SCHEMBL28798 | 0.69 | NR4A1 (0.65) | L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919365-B2 | Imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1384715-A1 | NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS | Senju Pharmaceutical Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | CMA1, TPSD1, TPSB2 | POLB 4384/4885TDP1 2741/4885MEN1 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.